Sanofi

YTD

ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories.

CEO

Olivier Antoine M. Charmeil

CEOOlivier Antoine M. Charmeil

Employees

76,493

Employees76,493

Headquarters

Paris, Ile-de-France

HeadquartersParis, Ile-de-France

Founded

1994

Founded1994

Employees

76,493

Employees76,493

SNY Key Statistics

Market cap

108.62B

Market cap108.62B

Price-Earnings ratio

18.70

Price-Earnings ratio18.70

Dividend yield

3.55%

Dividend yield3.55%

Average volume

4.46M

Average volume4.46M

High today

$44.78

High today$44.78

Low today

$44.00

Low today$44.00

Open price

$44.08

Open price$44.08

Volume

6.45M

Volume6.45M

52 Week high

$60.12

52 Week high$60.12

52 Week low

$44.00

52 Week low$44.00

SNY News

TipRanks 2d

Sanofi India Publishes Transcript of Investor Call on 2025 Financial Results

Sanofi India Limited ( (IN:SANOFI) ) has provided an update. Sanofi India Limited has notified the stock exchanges that it has made available the transcript of...

Simply Wall St 2d

Teva Blackstone Duvakitug Deal Tests Growth Story And Concentration Risk

Teva Pharmaceutical Industries (NYSE:TEVA) secured a multi year funding commitment of up to $400 million from Blackstone Life Sciences. The capital is earmarke...

TipRanks 2d

Sanofi Details CEO Paul Hudson’s February 2026 Departure Terms and Equity Awards

The latest announcement is out from Sanofi ( (SNY) ). Sanofi disclosed that Chief Executive Officer Paul Hudson’s mandate ended on February 17, 2026, and that...

Analyst ratings

67%

of 6 ratings

Buy

66.7%

Hold

33.3%

Sell

More SNY News

Simply Wall St 3d

Sanofi Rumored Bid And Regulatory Shifts Reframe Ocular Therapeutix Valuation

Rumors are circulating that Sanofi is considering a significantly higher acquisition bid for Ocular Therapeutix (NasdaqGM:OCUL). The speculation follows recent...

Nasdaq 5d

Sanofi: Rilzabrutinib Granted Orphan Drug Designation In Japan For IgG4-related Disease

(RTTNews) - Sanofi (SNY, SAN.PA) announced the Ministry of Health, Labour and Welfare in Japan has granted orphan drug designation to rilzabrutinib, an oral, re...

TipRanks 5d

Sanofi’s Blueprint Medicines presents data on Ayvakit ay AAAAI

Blueprint Medicines, a Sanofi (SNY) company, announced Ayvakit data showing clinically meaningful outcomes and a well-tolerated long-term safety profile in pati...

Simply Wall St 7d

Recursion’s First Clinical Signal And Sanofi Milestone Test AI Drug Thesis

Recursion Pharmaceuticals reported its first positive clinical proof-of-concept for REC-4881 in familial adenomatous polyposis. The company hit a fifth collabo...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.